Last reviewed · How we verify
Yondelis
At a glance
| Generic name | Yondelis |
|---|---|
| Sponsor | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. |
| Target | Proto-oncogene tyrosine-protein kinase Src, Nuclear receptor subfamily 1 group I member 2 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Approved indications
- Leiomyosarcoma
- Liposarcoma
- Malignant tumor of ovary
- Soft or Connective Tissue Sarcoma
Common side effects
- Nausea
- Fatigue
- Vomiting
- Constipation
- Decreased appetite
- Diarrhea
- Peripheral edema
- Dyspnea
- Headache
Serious adverse events
- Neutropenia
- Increased ALT
- Thrombocytopenia
- Anemia
- Increased AST
- Increased creatine phosphokinase
- Increased liver tests
- Decreased ejection fraction
- Febrile neutropenia
Key clinical trials
- Study on Trabectedin in Advanced Rearranged Mesenchymal Chondrosarcoma (PHASE2)
- Trial in Patients With Metastatic or Locally Advanced Leiomyosarcoma (PHASE2)
- Continuing vs Intermittent Trabectedin in Patients With Advanced Soft Tissue Sarcoma (PHASE2)
- Phase II Decentralized Pragmatic Trial of Adjuvant Doxorubicin - Trabectedin Chemotherapy in uLMS (PHASE2)
- Prospective Identification of Predictive Biomarkers of Trabectedin Efficacy in Non-L Soft-tissue Sarcoma Patients (NA)
- A Phase I Study of Pazopanib in Combination With Trabectedin, Ipilimumab and Nivolumab (TraPIN) in Pediatric and Young Adult Patients With Recurrent Soft Tissue Sarcomas (PHASE1)
- Study on Trabectedin in Combination With Pioglitazone in Patients Myxoid Liposarcomas With Stable Disease After T Alone. (PHASE2)
- Phase 1 Study of SON-1010 in Adult Patients With Advanced Solid Tumors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Yondelis CI brief — competitive landscape report
- Yondelis updates RSS · CI watch RSS
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C. portfolio CI